Paeds · clinical-pharmacology-and-therapeutics
Off-label and unlicensed medicine use
Also known as Off-label prescribing in children · Unlicensed medicine use in paediatrics · Paediatric specials and compounding · Use of medicines outside the product licence · Paediatric evidence gap
Fellowship guide to off-label and unlicensed medicine use in children: the three prescribing categories, why paediatric prescribing is so often outside the product licence, prevalence across settings, the link with adverse drug reactions, the safe-use governance pathway (licensed alternative, evidence, formulation, documentation, consent, monitoring and reporting), and the regional regulatory frameworks that are closing the paediatric evidence gap.
On this page
Study tools
Your progress
Saved on this device.
Practise this topic
Target exams
Red flags
- A child has an adverse drug reaction to a medicine prescribed outside its licence and it is not reported to the national pharmacovigilance scheme
- A high-risk off-label or unlicensed medicine (narrow therapeutic index, neonate, IV inotrope or sedative, compounded formulation) started without senior sign-off or Medicines Committee notification
- An extemporaneously compounded or imported 'special' supplied without a documented stability and quality check
- A family not told that a medicine is being used outside its licence, despite asking or despite a meaningful risk
- An unlicensed medicine continued long after a licensed paediatric alternative has become available
- A prescribing decision outside the licence made on memory alone, with no documented evidence base or paediatric reference
Life stages
Care settings
Clinical exam formats
Board mappings
- Pharmacology and safe prescribing
- Quality and safety of clinical care
- Professional qualities and patient safety
- Learning goal: safe and evidence-based prescribing across the age range, including off-label and unlicensed medicines
- Quality improvement and patient safety
- Professional practice and ethics
- Professional Qualities
- Clinical Applications and pharmacology and safe prescribing
- Long Cases involving a child on multiple off-label or unlicensed medicines
- Short Cases on the governance of off-label prescribing
- Communication stations on counselling a family that a medicine is off-label
- Safe prescribing and medication safety
- Patient safety and quality improvement
- Leadership and team working
- Foundation of Practice (FOP)
- Applied Knowledge in Practice (AKP)
- Communication
- History taking and management
- Patient safety station
- General Pediatrics Content Outline — pharmacology and safe prescribing
- General Pediatrics Content Outline — patient safety and quality improvement
- Systems-based practice and off-label prescribing governance
- Systems-Based Practice 1: Patient Safety and Quality Improvement
- Patient Care: safe and evidence-based prescribing
- Practice-Based Learning and Improvement: governance of off-label and unlicensed medicines
- Interpersonal and Communication Skills: counselling families on off-label use
- Medical Expert
- Collaborator
- Health Advocate
- Pediatric EPA — safe prescribing and medication safety
Overview & Definition
A registrar on a neonatal unit is asked to start caffeine citrate for apnoea of prematurity. The box is not licensed for the baby's gestational age and the strength on the ward is a pharmacy-made solution. The registrar hesitates. This leaf owns that moment — off-label and unlicensed medicine use — and the reasoning that turns it from a worry into a defensible, child-centred decision. The broader medication-safety and pharmacovigilance theory lives on its own leaves; this page is about the licence. [1] [5]
Hold three words apart, because examiners live in the gaps between them. A licensed (sometimes called on-label) medicine is used within all the terms of its marketing authorisation — the approved age or weight band, the approved indication, route, dose and formulation. An off-label medicine is a licensed product used outside one or more of those terms: the right drug, in a child of the wrong age, or for an unapproved indication, route or dose, or in a formulation that differs from the licensed one. An unlicensed medicine has no valid marketing authorisation for that product or formulation in the country at all — a pharmacy-made "special", an imported product, something extemporaneously compounded, or an investigational product in a clinical trial. [1] [6]
The reason this distinction matters clinically is that each category carries a different governance load. A licensed medicine comes with a regulator-vetted dose range, a tested formulation, and a post-marketing safety database. The moment you step outside the licence you take personal responsibility for the dose, evidence, formulation quality and the monitoring — because the regulator's safety net no longer covers that exact use. The rest of this page is about discharging that responsibility well. [7] [5]
References12ShowHide
- [1]Conroy S Survey of unlicensed and off label drug use in paediatric wards in European countries. European Network for Drug Investigation in Children. BMJ, 2000.PMID 10625257
- [2]'t Jong GW A survey of the use of off-label and unlicensed drugs in a Dutch children's hospital. Pediatrics, 2001.PMID 11694685
- [3]'t Jong GW Unlicensed and off-label prescription of respiratory drugs to children. Eur Respir J, 2004.PMID 14979509
- [4]Neubert A The impact of unlicensed and off-label drug use on adverse drug reactions in paediatric patients. Drug Saf, 2004.PMID 15471510
- [5]Cuzzolin L Off-label and unlicensed prescribing for newborns and children in different settings: a review of the literature and a consideration about drug safety. Expert Opin Drug Saf, 2006.PMID 16907660
- [6]Kimland E Off-label drug use in pediatric patients. Clin Pharmacol Ther, 2012.PMID 22472984
- [7]Frattarelli DA Off-label use of drugs in children. Pediatrics, 2014.PMID 24567009
- [8]Bellis JR Adverse drug reactions and off-label and unlicensed medicines in children: a nested case-control study of inpatients in a pediatric hospital. BMC Med, 2013.PMID 24229060
- [9]Nir-Neuman H Unlicensed and Off-Label Medication Use in Pediatric and Neonatal Intensive Care Units: No Change Over a Decade. Adv Ther, 2018.PMID 29949042
- [10]Lindell-Osuagwu L Prescribing for off-label use and unauthorized medicines in three paediatric wards in Finland, the status before and after the European Union Paediatric Regulation. J Clin Pharm Ther, 2014.PMID 24329556
- [11]Sohn M National trends in off-label use of atypical antipsychotics in children and adolescents in the United States. Medicine (Baltimore), 2016.PMID 27281081
- [12]Aurich B c4c: Paediatric pharmacovigilance: Methodological considerations in research and development of medicines for children - A c4c expert group white paper. Br J Clin Pharmacol, 2022.PMID 34699077